This inventor holds 1 USPTO granted patent. Top assignee: Bayer Healthcare Aktiengesellschaft. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Michael L Dumas: Innovator in Metabolic Disease Treatment
Introduction
Michael L Dumas is a notable inventor based in Richmond, CA (US). He has made significant contributions to the field of metabolic disease treatment through his innovative research and development of novel peptides. His work focuses on addressing issues related to insulin secretion and blood glucose levels, particularly in type 2 diabetes patients.
Latest Patents
Dumas holds a patent for the invention titled "Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide." This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides have been shown to lower blood glucose levels in vivo more effectively than controls upon glucose challenge. The polypeptides are stable in formulation and possess long half-lives. This invention offers a new therapy for patients with decreased endogenous insulin secretion, particularly those suffering from type 2 diabetes. The invention includes a polypeptide selected from a specific group of VPAC2-related polypeptides or their functional equivalents. Additionally, it outlines a method for treating metabolic diseases in mammals by administering a therapeutically effective amount of the insulin secretagogue peptides. Methods for making the peptides, both recombinant and synthetic, are also disclosed.
Career Highlights
Dumas is associated with Bayer Healthcare Aktiengesellschaft, where he continues to contribute to advancements in healthcare and therapeutic solutions. His work has been instrumental in developing treatments that can significantly improve the quality of life for individuals with metabolic disorders.
Collaborations
Dumas has collaborated with notable colleagues, including Clark Qun Pan and Drew N Kelner, to further enhance the research and development of innovative therapies in the field of metabolic diseases.
Conclusion
Michael L Dumas is a pioneering inventor whose work in developing VPAC2 receptor agonist peptides represents a significant advancement in the treatment of metabolic diseases. His contributions are poised to make a lasting impact on the management of type 2 diabetes and related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile